MRSA Research Today is a free monthly online journal that collates and summarizes the latest research about MRSA, including details on methicillin-resistant staphylococcus aureus, hospitals, infection, antibiotic resistance, superbugs.

Volume 5 (2008), Issue 3 (March)

1. Mortality after infection with methicillin-resistant Staphylococcus aureus (MRSA) diagnosed in the community.
   BMC Med, 6: 2. [Abstract] [Full-text]
2. Discovery of a quorum sensing inhibitor of drug resistant staphylococcal infections by structure-based virtual screening.
   Mol Pharmacol. [Abstract] [Full-text]
3. Risk factors and mortality in patients with nosocomial Staphylococcus aureus bacteremia.
   Am J Infect Control, 36(2): 118-22. [Abstract] [Full-text]
4. Methicillin-resistant Staphylococcus aureus transmission: the possible importance of unrecognized health care worker carriage.
   Am J Infect Control, 36(2): 93-7. [Abstract] [Full-text]
5. The antimicrobial activity of heyneanol A extracted from the root of taiwanese wild grape.
   J Appl Microbiol. [Abstract] [Full-text]
6. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review.
   Eur Respir J, 31(3): 625-32. [Abstract] [Full-text]
7. Use of a regional health information exchange to detect crossover of patients with MRSA between urban hospitals.
   J Am Med Inform Assoc, 15(2): 212-6. [Abstract] [Full-text]
8. Methicillin resistant Staphylococcus aureus colonization in pigs and pig farmers.
   Vet Microbiol, 128(3): 298-303. [Abstract] [Full-text]
9. Selective decontamination of the digestive tract.
   Curr Opin Infect Dis, 21(2): 179-83. [Abstract] [Full-text]
10. Community-associated methicillin-resistant Staphylococcus aureus skin infections: advances toward identifying the key virulence factors.
    Curr Opin Infect Dis, 21(2): 147-52. [Abstract] [Full-text]
11. The bacterial envelope as a target for novel anti-MRSA antibiotics.
    Trends Pharmacol Sci, 29(3): 124-34. [Abstract] [Full-text]
12. New and emerging treatment of Staphylococcus aureus infections in the hospital setting.
    Clin Microbiol Infect, 14: 32-41. [Abstract] [Full-text]
13. Evolving problems with resistant pathogens.
    Clin Microbiol Infect, 14: 3-14. [Abstract] [Full-text]
14. Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization.
    Chest, 133(3): 625-32. [Abstract] [Full-text]
15. Community-acquired methicillin-resistant Staphylococcus aureus infections: an emerging threat in Spain.
    Clin Microbiol Infect, 14(4): 377-80. [Abstract] [Full-text]
16. Genetic diversity of community-associated methicillin-resistant Staphylococcus aureus in southern Stockholm, 2000-2005.
    Clin Microbiol Infect, 14(4): 370-6. [Abstract] [Full-text]
17. Community-Associated CMRSA-10 (USA-300) is the Predominant Strain among Methicillin-Resistant Staphylococcus aureus Strains Causing Skin and Soft Tissue Infections in Patients Presenting to the Emergency Department of a Canadian Tertiary Care Hospital.
    J Emerg Med. [Abstract] [Full-text]
18. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    J Clin Microbiol, 46(3): 1132-6. [Abstract] [Full-text]
19. Severe necrotizing fasciitis in a human immunodeficiency virus-positive patient caused by methicillin-resistant Staphylococcus aureus.
    J Clin Microbiol, 46(3): 1144-7. [Abstract] [Full-text]
20. Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase.
    J Clin Microbiol, 46(3): 892-6. [Abstract] [Full-text]
21. Epidemiological characteristics of methicillin-resistant Staphylococcus aureus isolates from children with eczematous atopic dermatitis lesions.
    J Clin Microbiol, 46(3): 991-5. [Abstract] [Full-text]
22. Efficacies of Ceftobiprole Medocaril and Comparators in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Osteomyelitis.
    Antimicrob Agents Chemother. [Abstract] [Full-text]
23. Temporin A is effective in MRSA-infected wounds through bactericidal activity and acceleration of wound repair in a murine model.
    Peptides, 29(4): 520-8. [Abstract] [Full-text]
24. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients.
    JAMA, 299(10): 1149-57. [Abstract] [Full-text]
25. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis.
    J Cyst Fibros, 7(2): 123-7. [Abstract] [Full-text]
26. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers.
    Diagn Microbiol Infect Dis, 60(4): 433-6. [Abstract] [Full-text]
27. Glyconanobiotics: Novel carbohydrated nanoparticle antibiotics for MRSA and Bacillus anthracis.
    Bioorg Med Chem, 16(5): 2412-8. [Abstract] [Full-text]
28. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Diagn Microbiol Infect Dis, 60(4): 437-40. [Abstract] [Full-text]
29. Injecting drug use and community-associated methicillin-resistant Staphylococcus aureus infection.
    Diagn Microbiol Infect Dis, 60(4): 347-50. [Abstract] [Full-text]
30. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
    Diagn Microbiol Infect Dis, 60(4): 399-403. [Abstract] [Full-text]
31. Hemipelvic amputations for recalcitrant pelvic osteomyelitis.
    Injury, 39(4): 411-8. [Abstract] [Full-text]
32. Emergence of USA300 MRSA in a tertiary medical centre: implications for epidemiological studies.
    J Hosp Infect, 68(3): 208-13. [Abstract] [Full-text]
33. Methicillin-Resistant Staphylococcus aureus-Positive Surgical Site Infections in Face-lift Surgery.
    Arch Facial Plast Surg, 10(2): 116-23. [Abstract] [Full-text]
34. Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus.
    J Med Microbiol, 57: 452-6. [Abstract] [Full-text]
35. Prevalence of genes encoding extracellular virulence factors among meticillin-resistant Staphylococcus aureus isolates from the University Hospital, Olomouc, Czech Republic.
    J Med Microbiol, 57: 403-10. [Abstract] [Full-text]
36. Methicillin-resistant Staphylococcus aureus infection after living-donor liver transplantation in adults.
    Transpl Infect Dis, 10(2): 110-6. [Abstract] [Full-text]
37. Comparison of the cidal activity of tea tree oil and terpinen-4-ol against clinical bacterial skin isolates and human fibroblast cells.
    Lett Appl Microbiol, 46(4): 428-33. [Abstract] [Full-text]
38. Effect of Maturation on the Composition and Biological Activity of the Essential Oil of a Commercially Important Satureja Species from Turkey: Satureja cuneifolia Ten. (Lamiaceae).
    J Agric Food Chem, 56(6): 2260-5. [Abstract] [Full-text]
39. Detection of meticillin-resistant Staphylococcus aureus and Panton-Valentine leukocidin directly from clinical samples and the development of a multiplex assay using real-time polymerase chain reaction.
    Eur J Clin Microbiol Infect Dis. [Abstract] [Full-text]
40. Vancomycin revisited: a reappraisal of clinical use.
    Crit Care Clin, 24(2): 393-420. [Abstract] [Full-text]
41. The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
    Crit Care Clin, 24(2): 349-63. [Abstract] [Full-text]
42. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care.
    Crit Care Clin, 24(2): 249-60. [Abstract] [Full-text]
43. Vancomycin: understanding its past and preserving its future.
    South Med J, 101(3): 284-91. [Abstract] [Full-text]
44. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
    Antimicrob Agents Chemother, 52(4): 1401-6. [Abstract] [Full-text]
45. Spontaneous deletion of the methicillin resistance determinant, mecA, partially compensates for the fitness cost associated with high-level vancomycin resistance in Staphylococcus aureus.
    Antimicrob Agents Chemother, 52(4): 1221-9. [Abstract] [Full-text]
46. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
    Antimicrob Agents Chemother, 52(4): 1430-7. [Abstract] [Full-text]
47. Characterization of Staphylococcus aureus Nasal Carriage from Children Attending an Outpatient Clinic in Seoul, Korea.
    Microb Drug Resist, 14(1): 37-44. [Abstract] [Full-text]
48. Identification of the First Vancomycin Intermediate-Resistant Staphylococcus aureus (VISA) Isolate from a Hospital in Portugal.
    Microb Drug Resist, 14(1): 1-6. [Abstract] [Full-text]
49. A case report of the use of nanocrystalline silver dressing in the management of acute surgical site wound infected with MRSA to prevent cutaneous necrosis following revision surgery.
    Int J Low Extrem Wounds, 7(1): 45-8. [Abstract] [Full-text]
50. MRSA infection in lower extremity wounds.
    Int J Low Extrem Wounds, 7(1): 28-31. [Abstract] [Full-text]
51. Control of a hospital-wide vancomycin-resistant Enterococci outbreak.
    Am J Infect Control, 36(3): 206-11. [Abstract] [Full-text]
52. The carriage population of Staphylococcus aureus from Mali is composed of a combination of pandemic clones and the divergent PVL positive genotype ST152.
    J Bacteriol. [Abstract] [Full-text]
53. The risk of infection after nasal colonization with Staphylococcus aureus.
    Am J Med, 121(4): 310-5. [Abstract] [Full-text]

© 2004-2008 MRSA Research Today. All Rights Reserved.